ARP (USA) Pty Ltd has been granted the rights to commercialize 4JOINTZ® in the USA by Arthritis Relief Plus Ltd, an Australian Biotechnology company, which has developed, patented and successfully completed clinical studies of its unique botanical topical (4JOINTZ®) for pain, stiffness and swelling associated with osteoarthritis and other joint conditions.
It is anticipated that the 4JOINTZ® technology could potentially provide significant cost savings for the community by delaying the need for surgery and reducing medical intervention associated with the side effects of commonly used Non-Steroidal Anti Inflammatory Drugs (NSAIDS). 4JOINTZ® improves the quality of life for osteoarthritis sufferers providing relief for painful, stiff and swollen joints.
The company is dedicated to enabling osteoarthritis sufferers achieve Freedom to Move. Its patented technology has been substantiated by gold standard research published in peer-reviewed medical journals by both Australian and US research institutions, verifying the safety and efficacy of 4JOINTZ®. 4JOINTZ® is a unique ointment providing a new frontier in the effective management of osteoarthritis pain and stiffness.